TY - JOUR
T1 - Antagonist-mediated down-regulation of 5-hydroxytryptamine type 2 receptor gene expression
T2 - Modulation of transcription
AU - Toth, Miklos
AU - Shenk, Thomas
PY - 1994/6
Y1 - 1994/6
N2 - Prolonged exposure to an agonist results in a progressive loss of most G protein-coupled receptors, whereas exposure to an antagonist causes increased receptor response. The 5-hydroxytryptamine (5-HT)2 receptor is down- regulated by agonists but, paradoxically, antagonists can also elicit a decrease in receptor density. Here we show that long term treatment with serotonin or mianserin, an antagonist and antidepressant, results in reduced levels of both the 5-HT2 receptor and its RNA. Antagonist-induced down- regulation requires the presence of the 5-HT2 receptor, it occurs at the level of transcription, and it is mediated by a drug response sequence in the 5' flanking region of the 5-HT2 receptor gene. The effect of mianserin might result, at least in part, from its ability to modulate transcription.
AB - Prolonged exposure to an agonist results in a progressive loss of most G protein-coupled receptors, whereas exposure to an antagonist causes increased receptor response. The 5-hydroxytryptamine (5-HT)2 receptor is down- regulated by agonists but, paradoxically, antagonists can also elicit a decrease in receptor density. Here we show that long term treatment with serotonin or mianserin, an antagonist and antidepressant, results in reduced levels of both the 5-HT2 receptor and its RNA. Antagonist-induced down- regulation requires the presence of the 5-HT2 receptor, it occurs at the level of transcription, and it is mediated by a drug response sequence in the 5' flanking region of the 5-HT2 receptor gene. The effect of mianserin might result, at least in part, from its ability to modulate transcription.
UR - http://www.scopus.com/inward/record.url?scp=0028235547&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028235547&partnerID=8YFLogxK
M3 - Article
C2 - 7517496
AN - SCOPUS:0028235547
SN - 0026-895X
VL - 45
SP - 1095
EP - 1100
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 6
ER -